Dronedarone - Wikipedia

Dronedarone (development codename SR33589 and marketed as Multaq) is a drug by Sanofi-Aventis, mainly for the indication of cardiac arrhythmias. It was approved by ...

Multaq (Dronedarone Tablets): Side Effects, Interactions ...

Learn about Multaq (Dronedarone Tablets) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications.

Multaq (dronedarone) and Alcohol / Food Interactions

Do not consume grapefruit or grapefruit juice during treatment with dronedarone unless directed otherwise by your doctor. Grapefruit juice can increase the blood ...

Dronedarone (Multaq ): cardiovascular, hepatic and ...

Following new evidence of cardiovascular, hepatic and pulmonary risk, a review of dronedarone has concluded that the benefits of treatment continue to outweigh the ...

Dronedarone Uses, Side Effects & Warnings - Drugs.com

Physician reviewed dronedarone patient information - includes dronedarone description, dosage and directions.

Dronedarone - Informazioni sui farmaci

Il dronedarone è un nuovo antiaritmico strutturalmente simile all’amiodarone. Nella prevenzione della fibrillazione atriale si è dimostrato nettamente meno ...

ATRIAL FIBRILLATION: Dronedarone and Amiodarone-- Safety ...

Amiodarone effectively maintains sinus rhythm in patients with atrial fibrillation, but although dronedarone is less effective it has a better safety profile.

UpToDate - Evidence-Based Clinical Decision Support at the ...

INTRODUCTION. Dronedarone, a noniodinated congener of amiodarone, was developed as an antiarrhythmic agent for the maintenance of sinus rhythm in patients with atrial ...

Multaq 400mg tablets - Summary of Product Characteristics ...

Careful monitoring during dronedarone administration is recommended by regular assessment of cardiac, hepatic and pulmonary function (see below).

MULTAQ® (dronedarone) Tablets Prescribing Information

Dronedarone is metabolized by CYP 3A and is a moderate inhibitor of CYP 3A and CYP 2D6 and has potentially important pharmacodynamic interactions . Class I or III ...